Leading the Next Frontier in Treatment of Atopic Dermatitis
Time: 3:30 pm
day: Conference Day Two
Details:
- Insights into translating a novel mechanism of action from initial phenotypic identification through target deconvolution
- Data package for our novel, differentiated and oral agent in AD models in vivo benchmarked against leading standard-of-care therapies / MoAs
- Share preliminary data on anti-inflammatory mechanism of our agent and potential in indications beyond AD
